In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in ...

Palivizumab-eligible infants under the age of 1 year who had been born prematurely (gestational age, ≤35 weeks) or who had chronic lung disease of prematurity or hemodynamically significant congenital ...